🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Truist lifts American Healthcare REIT target on strong growth

EditorTanya Mishra
Published 03/09/2024, 14:14
AHR
-

Truist Securities has adjusted its outlook on American Healthcare REIT, Inc (NYSE: AHR), increasing the price target to $22 from the previous $17 while maintaining a Buy rating on the stock.

The revision follows the company's robust performance since its initial public offering (IPO) on February 6, 2024, which saw its shares surge by 72%, outpacing the 13% gain of the Vanguard Real Estate ETF (VNQ) during the same timeframe.

The analyst from Truist Securities highlighted that the real estate investment trust (REIT), specializing in healthcare properties, has experienced significant net operating income (NOI) growth, which led to better-than-expected results in the second quarter of 2024. This performance has prompted the firm to reiterate its Buy rating.

According to the analyst, American Healthcare REIT's improved access to equity and debt capital markets could further enhance the company's growth prospects. Despite the stock's recent outperformance, it is believed that the REIT still offers the most attractive forward funds from operations (FFO) and funds available for distribution (FAD) multiples over a three- and five-year horizon within Truist's healthcare REIT coverage.

In other recent news, American Healthcare REIT has seen several noteworthy developments. BofA Securities has revised its price target for the company, raising it from $19 to $27 and maintaining a Buy rating.

The adjustment follows recent management meetings which provided BofA Securities with a deeper understanding of the company's growth potential and the robustness of the Trilogy platform.

Truist Securities also adjusted its price target for American Healthcare REIT, raising it from $16 to $17, while keeping a Buy rating. The revised price target reflects a potential 24% total return, indicating faith in the company's growth prospects.

Analysts from firms such as Barclays (LON:BARC) Capital Inc., JMP Securities, KeyBanc, and RBC Capital Markets have given American Healthcare REIT an Overweight rating, highlighting the company's strategic positioning in the healthcare real estate market as a potential driver for Net Operating Income (NOI) growth.

InvestingPro Insights

As American Healthcare REIT, Inc (NYSE:AHR) garners attention with its impressive post-IPO performance, an analysis of real-time data from InvestingPro provides additional context for investors. The company's market capitalization stands at $2.85 billion, reflecting its status in the market. Despite the recent price surge, the stock shows a significant overvaluation in terms of earnings, with a negative P/E ratio of -54.06, indicating that it is not profitable over the last twelve months. However, the company's revenue has grown by 9.24% over the last twelve months as of Q2 2024, suggesting an expanding business scale.

One of the InvestingPro Tips highlights that American Healthcare REIT is expected to see net income growth this year, aligning with the optimistic outlook of Truist Securities. Another tip points out that the stock is currently trading near its 52-week high, with the price at 97.58% of the peak, which could indicate a level of market confidence in its future performance. For investors seeking a deeper analysis, InvestingPro offers additional tips on the company's financial health and market position.

With the current positive momentum, American Healthcare REIT's robust returns over the last year and recent months are notable. The stock has delivered a return of 63.85% year-to-date and a substantial 29.68% return over the last month. These figures underscore the stock's strong performance in the short term, which may be of interest to momentum investors. To explore more insights and tips, investors can access a wider array of data and analysis on InvestingPro, which includes numerous additional tips for American Healthcare REIT, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.